NCT02021409 - Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment Versus BAY85-3934 | Biotech Hunter

Enrollment

126

Participants

Timeline

Start Date

January 28, 2014

Primary Completion Date

October 15, 2015

Study Completion Date

November 23, 2015

Conditions

AnemiaRenal Insufficiency, Chronic

Interventions

DRUG

BAY85-3934

Oral doses of BAY 85-3934 will be available in multiples of 5, 25, and 75 mg tablets

BIOLOGICAL

Darbepoetin alfa

Trial Locations (51)

1036

Budapest

1872

Sofia

2250

Gosford

2500

Esztergom

3073

Reservoir

3400

Montana

4400

Pazardzhik

5500

Lovech

6000

Stara Zagora

6500

Baja

7400

Kaposvár

7624

Pécs

7900

Szigetvár

9300

Dobrich

23900

Lecco

25123

Brescia

26100

Cremona

27100

Pavia

28007

Madrid

28702

San Sebastián de los Reyes

38043

Grenoble

53127

Bonn

57023

Livorno

69495

Pierre-Bénite

80138

Napoli

410469

Oradea

540103

Târgu Mureş

2210001

Nahariya

3810101

Hadera

4428164

Kfar Saba

7827804

Ashkelon

802-8555

Kitakyushu

831-0016

Ōkawa

050-0083

Muroran

020-0066

Morioka

251-8550

Fujisawa

511-0061

Kuwana

260-8712

Chiba

810-8563

Fukuoka

388-8004

Nagano

15-540

Bialystok

26-610

Radom

010731

Bucharest

020475

Bucharest

420-767

Bucheon-si

08907

L'Hospitalet de Llobregat

06100

Ankara Univ. Medical Faculty, Ankara

06490

Baskent University Medical Faculty, Ankara

03540

Sifa University Medical Faculty, Izmir

CB2 0QQ

Cambridge

L7 8XP

Liverpool